Osteosarcoma accounts for the majority of bone cancer cases in younger populations, with approximately 1,000 new diagnoses annually in the United States alone. Despite intensive chemotherapy and surgical interventions, survival rates have plateaued for decades. The reasons for this stagnation include the tumor’s complex biology and its propensity for metastasis, which significantly limits the effectiveness of existing modalities. Genetic mutations in bone-forming mesenchymal cells and, in some cases, inherited predispositions have been implicated in the disease’s pathogenesis, but precise molecular targets for therapy have remained elusive.

The research team has capitalized on recent advances in CAR-T cell technology, which reprograms a patient’s own T cells to recognize and eradicate cancer cells. While CAR-T treatments have transformed outcomes for hematological malignancies such as leukemia and lymphoma, solid tumors like osteosarcoma present unique obstacles. Tumor heterogeneity, immune evasion mechanisms, and a suppressive microenvironment reduce the efficacy of traditional CAR-T approaches in these contexts.

Addressing these challenges, the team engineered CAR-T cells to specifically target Oncostatin M (OSM) receptors present on osteosarcoma cells. OSM is a cytokine involved in inflammation and tissue remodeling, and its receptor is aberrantly expressed on these tumors. By designing the CAR-T cells to recognize multiple receptor sites associated with OSM, the therapy achieves a more comprehensive identification and destruction of cancerous cells. This multi-targeting capability is critical in overcoming the limitations of prior CAR-T constructs that focused on singular antigens.

The experimental data, obtained through rigorous in vivo studies employing mouse models of human osteosarcoma, are compelling. OSM CAR-T cells exhibited robust cytotoxicity across diverse patient-derived tumor samples, effectively reducing tumor burden. Furthermore, the therapy demonstrated significant efficacy in combating metastatic lesions—an area where conventional treatment frequently fails. The ability of OSM CAR-T cells to infiltrate and eliminate tumors in secondary organs instills hope for patients with advanced disease presentations.

Technical evaluation of the immune response revealed that OSM CAR-T cells retain functional persistence and proliferate upon exposure to tumor antigens, a hallmark of effective immunotherapies. Cytokine profiling confirmed that these modified cells produce targeted inflammatory signals conducive to tumor lysis without inducing systemic toxicity. Importantly, preclinical safety assessments showed no off-target effects or detrimental impacts on healthy tissues expressing normal levels of OSM receptors.

This research underscores the critical role that a multidisciplinary, collaborative environment plays in transforming scientific discoveries into viable clinical strategies. The synergy between Case Western Reserve University’s research expertise and the clinical infrastructure of University Hospitals facilitated the rapid design, production, and testing of these next-generation CAR-T cells. The institutions’ integrated resources allowed for comprehensive evaluation from molecular engineering to functional immune assays.

Looking ahead, the research team anticipates translating these promising preclinical results into clinical trials within the next two years. Success in human patients could inaugurate a new treatment era for osteosarcoma, potentially minimizing reliance on invasive surgeries and toxic chemotherapeutics. Such targeted immunotherapies might also extend survival and improve quality of life, particularly for those with metastatic or refractory disease who currently face limited options.

Beyond osteosarcoma, the novel principle of exploiting ligand-based CAR-T targeting through OSM receptor recognition may offer a blueprint for tackling other solid tumors exhibiting complex antigenic profiles. This strategy leverages the immune system’s adaptability, enabling more precise and customizable cancer treatments. As CAR-T technology continues to evolve, addressing tumor microenvironment challenges and optimizing persistence will be crucial to broadening its impact.

The leadership of Dr. Reshmi Parameswaran, associate professor at Case Western Reserve’s Department of Medicine and a key investigator within the Case Comprehensive Cancer Center’s Immuno-Oncology Program, was instrumental in this achievement. Dr. Parameswaran highlighted the therapy’s potential to overcome long-standing barriers, emphasizing the critical unmet need for novel osteosarcoma treatments that provide both efficacy and reduced toxicity compared to current standards.

Osteosarcoma’s biology—marked by rapid, aberrant bone growth and a high metastatic potential—necessitates innovative approaches like OSM CAR-T. Traditional chemotherapy and surgery offer only incremental improvements, often accompanied by significant side effects and functional limitations. This new immunotherapy embodies a precision medicine approach that directs the immune system’s cytotoxic capacity strictly against malignant cells, minimizing collateral damage.

While the path from preclinical research to approved clinical application is complex and requires careful validation in human subjects, OSM CAR-T therapy’s preliminary success paves a hopeful road. If larger-scale trials confirm safety and efficacy, this treatment could emerge as a powerful weapon in the arsenal against pediatric and young adult bone cancers, fulfilling a four-decade void in meaningful therapeutic progress. The work exemplifies how targeted immunotherapies hold transformative promise for even the most challenging solid tumors.

Subject of Research: Animals
Article Title: Oncostatin-M Ligand-Based CAR-T Therapy Displays Robust Anti-Tumor Activity Against Osteosarcoma
News Publication Date: 17-Mar-2026
Web References: https://doi.org/10.1186/s12916-026-04729-8
References: BMC Medicine publication DOI 10.1186/s12916-026-04729-8
Image Credits: Case Western Reserve University
Keywords: Bone cancer, Osteosarcoma, CAR-T therapy, Immunotherapy, Oncostatin M, Solid tumors, Pediatric cancer, Metastasis, Immune engineering, Targeted therapy

At the heart of this innovation lies a sophisticated form of immunotherapy termed CAR-NKT cell therapy. Unlike conventional approaches that rely principally on CAR-T cells, which have shown remarkable success in hematological malignancies yet limited efficacy against solid tumors, this therapy employs invariant natural killer T (NKT) cells genetically engineered to express chimeric antigen receptors (CARs) specific to mesothelin, a cell surface protein abundantly expressed on TNBC cells. This engineered immune cell not only wields the specificity of CAR targeting but also harnesses the innate cytotoxic mechanisms of NKT cells, granting it enhanced versatility and potency against tumors.

This multipronged approach addresses the complex defense mechanisms of solid tumors. CAR-NKT cells utilize three independent yet complementary modalities to overcome tumor resilience. First, the engineered CAR receptor facilitates targeted recognition and elimination of mesothelin-expressing tumor cells, penetrating the often impenetrable tumor mass. Second, the natural killer receptors (NKRs) inherent to NKT cells recognize an extensive range of stress-induced ligands on malignant cells — over twenty molecular markers — thereby drastically reducing the likelihood of immune escape by the tumor through antigenic variation. Third, and perhaps most intriguingly, these CAR-NKT cells possess a unique T cell receptor (TCR) repertoire that modifies the tumor microenvironment by selectively depleting immunosuppressive cells, including regulatory T cells and myeloid-derived suppressor cells, recalibrating the immune landscape to favor tumor eradication.

Experimental validation using ex vivo human tumor samples from patients with advanced metastatic TNBC has demonstrated the robust cytolytic capacity of CAR-NKT cells, which consistently obliterated cancer cells across all tested samples. These findings underscore not only their potent antitumor efficacy but also their ability to dismantle the tumor’s immunosuppressive barriers, a feat that has eluded many prior immunotherapies. By directly eliminating the tumor’s protective shield, CAR-NKT cells re-enable endogenous immune components to participate more effectively in tumor clearance.

The implications of this technology extend beyond therapeutic efficacy to practical accessibility and scalability. Current autologous CAR-T therapies require harvesting and engineering patient-specific cells, processes that are prohibitively expensive and time-consuming, often costing hundreds of thousands of dollars per treatment and necessitating a critical delay unsuitable for rapidly progressing malignancies. In contrast, the UCLA team’s innovation leverages cord blood-derived CD34⁺ hematopoietic stem and progenitor cells (HSPCs) to mass-produce universal CAR-NKT cells in a scalable ex vivo manufacturing system. This strategy allows for the creation of an “off-the-shelf” cellular product that is immediately available, drastically reducing both cost and time-to-treatment to an estimated $5,000 per dose, potentially democratizing access to life-saving immunotherapies worldwide.

This platform’s universality is grounded in the intrinsic biology of NKT cells, which exhibit a degree of immune system compatibility across unrelated recipients. This critical attribute enables the creation of a universal donor-derived cell bank, sidestepping the immunological complications and graft-versus-host disease risks associated with allogeneic cell transplantation. The logistical advantages, combined with the multipronged immune targeting capability, position CAR-NKT therapy as a paradigm-shifting modality for not only TNBC but also other visceral malignancies.

Indeed, mesothelin’s expression is not confined to TNBC alone; it is prominently present in ovarian, pancreatic, and lung cancers, which collectively represent a significant subset of treatment-resistant solid tumors. As a result, the CAR-NKT cell platform holds substantial potential as a versatile immunotherapeutic that could tackle a broad spectrum of cancers with dire unmet clinical needs. This broad applicability amplifies its significance and potential impact on oncological practice.

As the preclinical data solidifies, the UCLA research team is advancing toward submission of investigational new drug applications to the U.S. Food and Drug Administration (FDA) to initiate first-in-human clinical trials. These trials will critically evaluate safety, dosing, and efficacy in patients, marking the final step before this transformative therapy can enter clinical practice. If clinical performance mirrors preclinical promise, CAR-NKT cell therapy may inaugurate a new era of accessible, effective immunotherapy for some of the most challenging cancers to treat.

The scientific community and patients alike will be watching closely as this technology progresses toward translation. The ingenuity of combining engineered CAR specificity with the natural killer and T cell receptor repertoire of NKT cells exemplifies the cutting edge of immune engineering. This multifaceted assault on cancer, in conjunction with a scalable production model, redefines the contours of cancer immunotherapy by merging precision medicine with universal applicability.

Moreover, the strategy addresses several limitations inherent in current immunotherapies such as tumor antigen heterogeneity, immune evasion, prohibitive cost, and manufacturing bottlenecks. By overcoming these barriers, CAR-NKT cell therapy not only expands on the successes of CAR-T therapies but also charts a course for the next generation of cellular treatments for solid tumors.

In essence, the work by the UCLA team represents a beacon of hope for patients battling TNBC— a cancer subtype that has languished without effective targeted treatments. The convergence of immunology and synthetic biology in this innovative platform heralds a future where even the most formidable cancers can be targeted with precision, potency, and practicality.

As this research advances into clinical testing, it offers a potent reminder of the power of immune-based interventions to revolutionize cancer care and transform patient outcomes.

Subject of Research: Human tissue samples

Article Title: Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

News Publication Date: 13-Oct-2025

Web References:
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01736-9

References:
DOI: 10.1186/s13045-025-01736-9

Image Credits:
Lili Yang Lab/UCLA

Keywords:
Breast cancer, Immune cells, Immunotherapy, Cell therapies

CAR T cells represent a revolutionary approach in oncology, effectively turning a patient’s immune system into a tailored weapon against cancer. By genetically modifying T cells to express chimeric antigen receptors (CARs), researchers have enabled these immune cells to target and destroy malignant cells selectively. This technique has shown extraordinary success in curing patients suffering from previously untreatable blood cancers, such as specific types of leukemia and lymphomas. However, the broad application of this therapy remains challenging due to the fact that many patients do not respond favorably. This shortcoming is often attributable to the intrinsic limitations of T cells, which can diminish their effectiveness in the hostile tumor microenvironment.

The new study spearheaded by Paul Datlinger and his colleagues at CeMM has led to the creation of a transformative platform known as CELLFIE—short for CAR T cell engineering and high-content CRISPR screening technology. This comprehensive approach permits the systematic modification of CAR T cells at the genetic level, enabling researchers to screen for gene knockouts that improve the functionality and persistence of these therapeutic cells. Utilizing cutting-edge CRISPR technology, the researchers were able to test the impact of knocking out various human genes on CAR T cell performance, providing them with invaluable insights into genetic factors that enhance tumor-fighting abilities.

One of the most remarkable findings from this research was the identification of the RHOG gene as a critical target for increasing the potency of CAR T cells. Through systematic screening, the team discovered that the knockout of the RHOG gene led to a marked enhancement in the T cells’ abilities to combat leukemia in preclinical models. This insight underscores the complexity of CAR T cell functionality; while these cells have been engineered to perform a specific task, certain genetic factors that may bolster a natural immune response can paradoxically undermine their effectiveness in engineered forms, highlighting the nuanced interplay of genetics in immune response.

Eugenia Pankevich, a co-first author on the paper, elaborates on the significance of their findings. The researchers have demonstrated that certain genes, while crucial for natural immune functions, can hinder the effectiveness of CAR T therapies. By utilizing CRISPR technology to eliminate these counterproductive genetic components, the research team was able to enhance the overall therapeutic potential of CAR T cells significantly. This novel application of gene editing provides an exciting avenue for creating more effective cancer treatments that could drastically alter the prognosis for many patients.

In their pursuit of advancing CAR T cell therapy, the researchers employed their CELLFIE platform to evaluate the effects of thousands of gene knockouts comprehensively. In particular, they sought to identify genetic modifications that would allow the engineered T cells to persist longer in the body, resist exhaustion, and enhance their proliferative capacity when faced with tumor cells. The research incorporated an innovative in vivo CRISPR screening approach, corroborating the beneficial effects of specific genetic modifications in real-time within preclinical mouse models, a promising strategy that could streamline future clinical applications.

The discovery did not stop with the RHOG knockout. The team found that combining knockouts of RHOG with another gene known as FAS resulted in synergistic effects that significantly improved the therapeutic profile of CAR T cells. By knocking out both genes, the engineered cells demonstrated faster proliferation rates, increased activity levels, and a markedly greater ability to cure aggressive leukemia in murine models. This revelation opens up exciting possibilities for combinatorial genetic modifications in CAR T cell therapy, suggesting that a multi-target approach could enhance treatment outcomes even further.

Beyond immediate applications in blood cancers, the CELLFIE platform promises broader implications for immunotherapy. The technology presents a customizable framework capable of integrating genome-wide screenings and optimization protocols that aim to tailor immune therapies for a range of cancers, including traditionally harder-to-treat solid tumors. The potential to adapt these precision therapies further to address autoimmune disorders and regenerative medicine challenges presents a compelling opportunity for optimizing patient care based on individual genetic and immune profiles.

Christoph Bock, the principal investigator in the study, articulates the long-term vision for this research. By establishing a robust methodology for systematically enhancing cell-based immunotherapies, scientists are poised to pave the way for the next generation of immune therapies. As researchers delve deeper into understanding the programming of T cells as effective anti-cancer agents, the future of medicine may lie in these ‘living drugs’ that possess the ability to adapt and respond dynamically to various diseases.

The implications of this study are profound, particularly as clinical validation processes begin. The researchers are optimistic about undertaking clinical trials to assess the monumental potential of RHOG and FAS knockout CAR T cells in human subjects suffering from various forms of cancer. In particular, the promising synergy observed with dual gene knockouts could herald a new era of more effective treatments that incorporate multiple genetic targets.

As CAR T cell therapy continues to revolutionize cancer treatment landscapes, the prospects of enhancing efficacy through innovative genetic strategies like those outlined in this study may ultimately lead to broader applications and increased access for patients. With the introduction of CELLFIE and the promise of genetic modifications to enhance the power and persistence of CAR T cells, the boundaries of what is possible in cancer immunotherapy are expanding. This research not only enhances our understanding of the complexities of immune system dynamics but also represents a significant leap forward in the efficacy of personalized medicine.

As this field gains momentum, it is imperative for the scientific community to continue exploring these pathways. The evolution of CAR T cells into more effective therapies not only has the potential to save countless lives but also paves the way for re-imagining our approach to battling a wider spectrum of diseases. The intersection of genetics and immune therapy is rapidly evolving, with research like that conducted by the CeMM leading the charge towards a brighter future in oncology and beyond.

As the world eagerly awaits further developments in this exciting field, the researchers at CeMM and the Medical University of Vienna stand at the forefront of a transformative journey aimed at reshaping cancer treatment and improving patient outcomes through meticulous scientific exploration and innovation.

Subject of Research: Cells
Article Title: Systematic discovery of CRISPR-boosted CAR T cell immunotherapies
News Publication Date: 24-Sep-2025
Web References: Nature Journal
References:
Image Credits: © Arc Institute; Wolfgang Däuble/CeMM

Keywords

Unlike traditional immunotherapies that require personalization by extracting, engineering, and re-infusing a patient’s own immune cells, AlloCAR70-NKT offers an off-the-shelf solution. This means the therapy can be mass-produced and readily available for any patient, circumventing the complex and time-consuming process of individual customization. This advancement could be revolutionary for patients battling rapidly progressing or advanced-stage kidney cancer, where time is critical, and conventional treatments often fail.

The team achieved this innovation by genetically programming natural killer T (NKT) cells, a unique subset of immune cells with innate cancer-fighting capabilities, derived from pluripotent stem cells. By equipping these NKT cells with a chimeric antigen receptor (CAR) specifically targeting CD70—a protein abundantly expressed on kidney cancer cells—the cells gain refined specificity, enabling them to identify and eradicate malignant cells more effectively. This precision targeting helps overcome challenges faced by existing CAR-T cell therapies, which have struggled with solid tumors due to inadequate tumor infiltration and the suppressive tumor microenvironment.

One of the defining features of AlloCAR70-NKT is its designed resistance to immune rejection. Typically, donor-derived immune cells risk being attacked and eliminated by the patient’s immune system, limiting their lifespan and therapeutic impact. The engineering process equips these cells to evade host immune responses, allowing them to persist longer in the patient’s body to sustain their anti-tumor activity while minimizing risks linked to chronic immune complications like graft-versus-host disease.

Preclinical studies revealed that the AlloCAR70-NKT cells orchestrate a strikingly comprehensive assault on kidney cancer. Firstly, these engineered cells kill tumor cells directly by leveraging both their CAR targeting CD70 and intrinsic NKT cell receptors. Remarkably, this dual recognition enables them to eliminate cancer cells even when CD70 expression is low—a common escape route tumors use to evade standard CAR therapies. This dual mechanism presents a significant advancement in ensuring thorough tumor clearance.

The therapy also confronts the challenge posed by the tumor microenvironment, a notoriously protective niche composed of immunosuppressive cells and molecules that shelter cancer cells from immune attack. AlloCAR70-NKT cells disrupt this environment, degrading the defensive barrier and rendering the tumor more vulnerable to immune system assault. By remodeling the microenvironment, the therapy not only attacks cancer but also weakens the tumor’s ability to resist treatment, potentially reducing relapse.

Another critical element of this multi-pronged approach is the elimination of CD70-positive host immune cells that would normally recognize and reject transplanted cells. By selectively targeting these host cells, the engineered NKT cells extend their own survival and function inside the patient, creating a more sustained therapeutic window. This strategic targeting helps maintain the presence and potency of the infused cells without permanently compromising the overall immune system.

Importantly, AlloCAR70-NKT cells are designed with a self-limiting lifespan within the body. They do not engraft permanently, substantially lowering the risk of prolonged immune suppression or autoimmune reactions, which have been troubling concerns in previous cellular immunotherapies. This safer profile enhances the therapy’s appeal, especially for patients with fragile immune systems or those suffering advanced-stage disease.

The breakthrough emerges from a collaboration of scientists across UCLA’s Jonsson Comprehensive Cancer Center and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, blending expertise in molecular pharmacology, immunology, and regenerative medicine. The research, co-led by Drs. Lily Wu, Lili Yang, and Arnold Chin, underscores the power of interdisciplinary innovation in overcoming complex biological hurdles.

Published in Cell Reports Medicine, the study delineates not only proof-of-concept efficacy in preclinical models but also illuminates the molecular engineering strategies behind this therapy’s success. By capitalizing on stem cell biology to generate a consistent and scalable source of immune cells, the researchers outline a path toward more reliable and cost-effective production of cellular therapies.

This promising advance could transform outcomes for patients diagnosed with metastatic renal cell carcinoma, a disease notoriously resistant to both immunotherapy and targeted agents. Currently, the five-year survival rate lingers at an unacceptably low 12%, signaling an urgent clinical need that AlloCAR70-NKT seeks to address.

The approach opens avenues for expanding the therapeutic landscape beyond kidney cancer, inspiring the development of similar “off-the-shelf” immunotherapies geared to tackle a variety of solid tumors. By efficiently overcoming tumor-specific immune evasion tactics and the suppressive microenvironment, this therapy exemplifies the next generation of intelligent cancer treatments.

With ongoing support from organizations such as the California Institute for Regenerative Medicine, the Parker Institute for Cancer Immunotherapy, and the U.S. Department of Defense’s Kidney Cancer Research Program, the UCLA team is advancing toward clinical translation. Their goal is to validate the safety and efficacy of AlloCAR70-NKT in human patients, hoping to bring new hope to individuals facing this formidable disease.

This innovative therapy epitomizes a significant stride in cancer immunology, offering a multi-dimensional, scalable, and safer cellular immunotherapy. If successful in clinical settings, AlloCAR70-NKT could redefine treatment paradigms for metastatic kidney cancer, illuminating a path toward improved survival and quality of life for many patients worldwide.

Subject of Research: Immunotherapy for metastatic renal cell carcinoma using engineered allogeneic CAR-NKT cells derived from stem cells.

Article Title: Not specified in the text.

Web References:

• https://doi.org/10.1016/j.xcrm.2025.102321
• https://www.uclahealth.org/cancer/members/lily-wu
• https://www.uclahealth.org/cancer/members/lili-yang
• https://www.uclahealth.org/cancer/members/arnold-chin

References:

• Study published in Cell Reports Medicine, DOI: 10.1016/j.xcrm.2025.102321

Image Credits: Not provided.

Keywords: Kidney cancer, Cancer immunology, Immunotherapy, CAR-NKT cells, Stem cell-derived immune therapy, Metastatic renal cell carcinoma